CMS will announce the next round of drugs to be included in the Medicare Drug Price Negotiation Program (MDPNP) on February 1, 2026. Absent Congressional intervention, changes to Medicare will force patients into higher-cost hospital settings, disrupt physician-patient decision making, and raise overall healthcare costs.

While MDPNP was designed to lower costs, its reimbursement structure creates a critical flaw for infusion providers in the rheumatology community. The program’s pricing model fails to account for the costs that providers absorb daily: acquisition costs, handling and storage requirements, clinical oversight, patient education, adverse event management, and the overhead of maintaining a safe, accredited infusion facility.

Luckily, Congress can act to solve this problem! The bipartisan Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299) fixes this issue by removing providers like you from the middle of Medicare negotiations.

As a provider on the front lines, your perspective matters to Congress. Legislators need to hear directly from infusion providers and practice operators about the real-world consequences of inadequate reimbursement. It takes just a few minutes to send a letter to your lawmakers through the Legislative Action Center- take action today!